PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Sees Large Decline in Short Interest

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,700 shares, a drop of 49.7% from the February 13th total of 29,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 0.8 days.

PharmaCyte Biotech Stock Performance

Shares of NASDAQ:PMCB traded down $0.09 during midday trading on Friday, reaching $1.58. 25,255 shares of the company’s stock traded hands, compared to its average volume of 24,421. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58. The company has a market cap of $10.85 million, a price-to-earnings ratio of 2.98 and a beta of -0.25. The stock has a 50 day moving average of $1.65 and a 200 day moving average of $1.69.

PharmaCyte Biotech (NASDAQ:PMCB) last issued its quarterly earnings data on Friday, December 13th. The company reported ($0.29) earnings per share for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.